Adaptive Biotechnologies Corp

ADPT is exhibiting a clear Stage 2 advance with sustained acceptance above rising EMAs despite extreme overbought readings. Price remains tightly tracking the 9- and 20-day EMAs, and recent pullbacks have been shallow and quickly absorbed. The momentum-oriented environment supports buying now on minor retracements into the 9-day EMA to capture further trend acceleration.

• ↑Q2 2026 revenue reached $71.6M, up 30% YoY, led by a 49% MRD surge
• ↑Adjusted EBITDA jumped to $9.1M from $1.9M YoY, boosting operating margins
• ↓Net loss of $39.9M in Q2 intensifies cash-burn and funding risks